These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28262921)

  • 1. Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Lin CJ; Vader JM; Slade M; DiPersio JF; Westervelt P; Romee R
    Cancer; 2017 May; 123(10):1800-1809. PubMed ID: 28262921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
    Nakamae H; Koh H; Katayama T; Nishimoto M; Hayashi Y; Nakashima Y; Nakane T; Nakamae M; Hirose A; Hino M
    Exp Hematol; 2015 Nov; 43(11):921-929.e1. PubMed ID: 26284307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML.
    Rashidi A; Slade M; DiPersio JF; Westervelt P; Vij R; Romee R
    Bone Marrow Transplant; 2016 Dec; 51(12):1561-1564. PubMed ID: 27526282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors.
    Alidina A; Lawrence D; Ford LA; Baer MR; Bambach B; Bernstein SH; Czuczman MS; Slack JL; Spangenthal E; Wetzler M; Barcos MP; Proulx GM; Anderson B; McCarthy PL
    Biol Blood Marrow Transplant; 1999; 5(5):322-7. PubMed ID: 10534063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
    Mori T; Koh H; Onishi Y; Kako S; Onizuka M; Kanamori H; Ozawa Y; Kato C; Iida H; Suzuki R; Ichinohe T; Kanda Y; Maeda T; Nakao S; Yamazaki H
    Int J Hematol; 2016 Apr; 103(4):461-8. PubMed ID: 26910242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.
    Zver S; Zadnik V; Černelč P; Koželj M
    Int J Hematol; 2008 Sep; 88(2):227-236. PubMed ID: 18548196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    Zver S; Zadnik V; Bunc M; Rogel P; Cernelc P; Kozelj M
    Int J Hematol; 2007 Jun; 85(5):408-14. PubMed ID: 17562616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
    Kerbauy FR; Tirapelli B; Akabane H; Oliveira JS
    Bone Marrow Transplant; 2009 Jun; 43(11):883-5. PubMed ID: 19079309
    [No Abstract]   [Full Text] [Related]  

  • 12. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.
    Thakar MS; Broglie L; Logan B; Artz A; Bunin N; Burroughs LM; Fretham C; Jacobsohn DA; Loren AW; Kurtzberg J; Martinez CA; Mineishi S; Nelson AS; Woolfrey A; Pasquini MC; Sorror ML
    Blood; 2019 Feb; 133(7):754-762. PubMed ID: 30545834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
    Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
    Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
    Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
    Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Vuolteenaho O; Ala-Kopsala M; Nousiainen T; Hartikainen J
    Eur J Haematol; 2006 Aug; 77(2):120-7. PubMed ID: 16856907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.
    Russo A; Oliveira G; Berglund S; Greco R; Gambacorta V; Cieri N; Toffalori C; Zito L; Lorentino F; Piemontese S; Morelli M; Giglio F; Assanelli A; Stanghellini MTL; Bonini C; Peccatori J; Ciceri F; Luznik L; Vago L
    Blood; 2018 Jan; 131(2):247-262. PubMed ID: 28986344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
    Kim H; Lee KH; Kim I; Sohn SK; Jung CW; Joo YD; Kim SH; Kim BS; Choi JH; Kwak JY; Kim MK; Bae SH; Shin HJ; Won JH; Lee WS; Oh S; Kim HJ; Park JH;
    Leuk Res; 2014 Jul; 38(7):730-6. PubMed ID: 24840870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I.
    Yamashita M; Eguchi S; Tomomasa D; Kamiya T; Niizato D; Mitsuiki N; Isoda T; Funakoshi H; Mizuno Y; Okamoto K; Nguyen TM; Takada H; Takagi M; Imai K; Morio T; Kanegane H
    Front Immunol; 2022; 13():1020362. PubMed ID: 36353617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.